This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dutta, S.
Right arrow Articles by Lanar, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dutta, S.
Right arrow Articles by Lanar, D. E.

 Previous Article  |  Next Article 

Infection and Immunity, September 2005, p. 5936-5944, Vol. 73, No. 9
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.9.5936-5944.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Merozoite Surface Protein 1 of Plasmodium vivax Induces a Protective Response against Plasmodium cynomolgi Challenge in Rhesus Monkeys{dagger}

Sheetij Dutta,1 Deep C. Kaushal,2 Lisa A. Ware,1 Sunil K. Puri,3 Nuzhat A. Kaushal,3 Atul Narula,2 D. S. Upadhyaya,4 and David E. Lanar1*

Department of Immunology, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910,1 Division of Microbiology,2 Division of Parasitology,3 Division of Lab Animals, Central Drug Research Institute, Lucknow 226001, India4

Received 11 March 2005/ Returned for modification 22 April 2005/ Accepted 11 May 2005

The 42-kDa fragment of the merozoite surface protein 1 (MSP-142) is a leading candidate for the development of a vaccine to control malaria. We previously reported a method for the production of Plasmodium vivax MSP-142 (PvMSP-142) as a soluble protein (S. Dutta, L. W. Ware, A. Barbosa, C. F. Ockenhouse, and D. E. Lanar, Infect. Immun. 69:5464-5470, 2001). We report here a process to manufacture the same PvMSP-142 protein but as an insoluble inclusion body-derived protein which was then refolded in vitro. We compared the immunogenicity and protective efficacy of the soluble and refolded forms of PvMSP-142 protein by using a heterologous but closely related P. cynomolgi-rhesus monkey challenge model. As comparative controls we also expressed, purified, and immunized rhesus with the soluble and refolded forms of the P. cynomolgi MSP-142 (PcMSP-142) proteins. All proteins induced equally high-titer, cross-reacting antibodies. Upon challenge with P. cynomolgi, none of the MSP-142-vaccinated groups demonstrated sterile protection or a delay in the prepatent period. However, following an initial rise in parasitemia, all MSP-1-vaccinated animals had significantly lower parasite burdens as indicated by lower cumulative parasitemia, lower peak parasitemia, lower secondary peak parasitemia, and lower average daily parasitemia compared to the adjuvant control group (P < 0.05). Except the soluble PcMSP-142 group, monkeys in all other groups had fewer numbers of days with parasitemia of >10,000 parasites mm–3. Interestingly, there was no significant difference in the level of partial protection observed in the homologous and heterologous groups in this challenge model. The soluble and refolded forms of PcMSP-142 and PvMSP-142 proteins also appeared to have a similar partially protective effect.

* Corresponding author. Mailing address: Department of Immunology, Walter Reed Army Institute of Research, Silver Spring, MD 20910. Phone: (301) 319-9003. Fax: (202) 319-7594. E-mail: david.lanar{at}us.army.mil.

{dagger} CDRI communication no. 6711.

Editor: W. A. Petri, Jr.

Infection and Immunity, September 2005, p. 5936-5944, Vol. 73, No. 9
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.9.5936-5944.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Collins, W. E., Sullivan, J. S., Warren, M., Galland, G. G., Williams, A., Barnwell, J. W. (2009). Plasmodium fieldi: Observations on the Hackeri and ABI Strains in Macaca mulatta Monkeys and Mosquitoes. Am J Trop Med Hyg 80: 739-744 [Abstract] [Full Text]  
  • Stanisic, D. I., Richards, J. S., McCallum, F. J., Michon, P., King, C. L., Schoepflin, S., Gilson, P. R., Murphy, V. J., Anders, R. F., Mueller, I., Beeson, J. G. (2009). Immunoglobulin G Subclass-Specific Responses against Plasmodium falciparum Merozoite Antigens Are Associated with Control of Parasitemia and Protection from Symptomatic Illness. Infect. Immun. 77: 1165-1174 [Abstract] [Full Text]  
  • HIGGS, E. S., SINA, B. (2005). PLASMODIUM VIVAX VACCINE RESEARCH: STEPS IN THE RIGHT DIRECTION. Am J Trop Med Hyg 73: 1-2 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»